FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562380304> ?p ?o ?g. }

• W2562380304 endingPage "4638" @default.
• W2562380304 startingPage "4638" @default.
• W2562380304 abstract "4638 Background: ARQ 197 is a selective, oral, non-ATP-competitive, small-molecule inhibitor of the c-MET receptor tyrosine kinase. Preclinical and phase I data suggested a possible role for c-MET in the pathophysiology of GCTs and a potential clinical benefit from ARQ 197 in GCT patients. Methods: Men (≥ 16 years of age) with relapsed or refractory, histologically confirmed, non-central nervous system GCTs received continuous oral ARQ 197 (360 mg twice daily in 28-day cycles) until progressive disease (PD) or unacceptable toxicity. Responses were assessed every 4 weeks during the first 4 cycles, and every 8 weeks thereafter per RECIST v1.1. The primary endpoint was objective response rate within the first 4 cycles, with study termination for < 2 responses amongst the first 21 patients (Simon 2-stage optimal design). Secondary endpoints included 12-week progression-free survival (PFS), overall survival (OS), and safety. Results: 27 patients (median age, 32 years) were enrolled from 9 sites in the US and Europe from February 2010 to November 2010. 25 had non-seminoma histology. Primary tumor sites included testis in 24, and mediastinum in 3. ECOG performance status was 0 (n = 9) or 1 (n = 18). All patients had received ≥ 2 prior lines of chemotherapy and 19/27 (70%) had received high-dose chemotherapy. Among 25 patients evaluable for efficacy, there were no objective responses and accrual was halted once the 21st patient became evaluable. Best response was stable disease in 7 and PD in 18. Median PFS was 32 days (95% CI = 29, 52) and 12-week PFS rate was 14%. Less than half (n = 12) patients have died. Reported grade 3/4 adverse events considered related to study drug were rare and included grade 3 pneumonia and grade 3 syncope (n = 1, each). Conclusions: ARQ 197 was well tolerated but did not demonstrate activity as a single agent in patients with relapsed/refractory GCTs. Correlative biologic data is pending but may provide insight into the lack of efficacy observed. Rapid accrual to this phase II trial was achieved in this rare patient population through multicenter collaboration. Future collaborative trials of novel targeted agents with sound biologic rationale are warranted in relapsed/refractory GCTs." @default.
• W2562380304 created "2017-01-06" @default.
• W2562380304 creator A5001456598 @default.
• W2562380304 creator A5018531384 @default.
• W2562380304 creator A5027991868 @default.
• W2562380304 creator A5031088617 @default.
• W2562380304 creator A5032890910 @default.
• W2562380304 creator A5035439869 @default.
• W2562380304 creator A5047251095 @default.
• W2562380304 creator A5048660181 @default.
• W2562380304 creator A5059063118 @default.
• W2562380304 creator A5065958068 @default.
• W2562380304 creator A5078274204 @default.
• W2562380304 creator A5086173392 @default.
• W2562380304 creator A5091169382 @default.
• W2562380304 date "2011-05-20" @default.
• W2562380304 modified "2023-10-17" @default.
• W2562380304 title "A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs)." @default.
• W2562380304 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.4638" @default.
• W2562380304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28023958" @default.
• W2562380304 hasPublicationYear "2011" @default.
• W2562380304 type Work @default.
• W2562380304 sameAs 2562380304 @default.
• W2562380304 citedByCount "2" @default.
• W2562380304 countsByYear W25623803042012 @default.
• W2562380304 countsByYear W25623803042013 @default.
• W2562380304 crossrefType "journal-article" @default.
• W2562380304 hasAuthorship W2562380304A5001456598 @default.
• W2562380304 hasAuthorship W2562380304A5018531384 @default.
• W2562380304 hasAuthorship W2562380304A5027991868 @default.
• W2562380304 hasAuthorship W2562380304A5031088617 @default.
• W2562380304 hasAuthorship W2562380304A5032890910 @default.
• W2562380304 hasAuthorship W2562380304A5035439869 @default.
• W2562380304 hasAuthorship W2562380304A5047251095 @default.
• W2562380304 hasAuthorship W2562380304A5048660181 @default.
• W2562380304 hasAuthorship W2562380304A5059063118 @default.
• W2562380304 hasAuthorship W2562380304A5065958068 @default.
• W2562380304 hasAuthorship W2562380304A5078274204 @default.
• W2562380304 hasAuthorship W2562380304A5086173392 @default.
• W2562380304 hasAuthorship W2562380304A5091169382 @default.
• W2562380304 hasConcept C121332964 @default.
• W2562380304 hasConcept C126322002 @default.
• W2562380304 hasConcept C141071460 @default.
• W2562380304 hasConcept C142424586 @default.
• W2562380304 hasConcept C143998085 @default.
• W2562380304 hasConcept C203092338 @default.
• W2562380304 hasConcept C2776694085 @default.
• W2562380304 hasConcept C2776938808 @default.
• W2562380304 hasConcept C2778822529 @default.
• W2562380304 hasConcept C31760486 @default.
• W2562380304 hasConcept C535046627 @default.
• W2562380304 hasConcept C71924100 @default.
• W2562380304 hasConcept C87355193 @default.
• W2562380304 hasConcept C90924648 @default.
• W2562380304 hasConceptScore W2562380304C121332964 @default.
• W2562380304 hasConceptScore W2562380304C126322002 @default.
• W2562380304 hasConceptScore W2562380304C141071460 @default.
• W2562380304 hasConceptScore W2562380304C142424586 @default.
• W2562380304 hasConceptScore W2562380304C143998085 @default.
• W2562380304 hasConceptScore W2562380304C203092338 @default.
• W2562380304 hasConceptScore W2562380304C2776694085 @default.
• W2562380304 hasConceptScore W2562380304C2776938808 @default.
• W2562380304 hasConceptScore W2562380304C2778822529 @default.
• W2562380304 hasConceptScore W2562380304C31760486 @default.
• W2562380304 hasConceptScore W2562380304C535046627 @default.
• W2562380304 hasConceptScore W2562380304C71924100 @default.
• W2562380304 hasConceptScore W2562380304C87355193 @default.
• W2562380304 hasConceptScore W2562380304C90924648 @default.
• W2562380304 hasIssue "15_suppl" @default.
• W2562380304 hasLocation W25623803041 @default.
• W2562380304 hasOpenAccess W2562380304 @default.
• W2562380304 hasPrimaryLocation W25623803041 @default.
• W2562380304 hasRelatedWork W1980324865 @default.
• W2562380304 hasRelatedWork W2023031195 @default.
• W2562380304 hasRelatedWork W2032110158 @default.
• W2562380304 hasRelatedWork W2248788750 @default.
• W2562380304 hasRelatedWork W2473626106 @default.
• W2562380304 hasRelatedWork W2562380304 @default.
• W2562380304 hasRelatedWork W2590956466 @default.
• W2562380304 hasRelatedWork W2593294044 @default.
• W2562380304 hasRelatedWork W2620160838 @default.
• W2562380304 hasRelatedWork W3171492215 @default.
• W2562380304 hasVolume "29" @default.
• W2562380304 isParatext "false" @default.
• W2562380304 isRetracted "false" @default.
• W2562380304 magId "2562380304" @default.
• W2562380304 workType "article" @default.